Cyclophosphamide
- Generic Name
- Cyclophosphamide
- Brand Names
- Procytox
- Drug Type
- Small Molecule
- Chemical Formula
- C7H15Cl2N2O2P
- CAS Number
- 50-18-0
- Unique Ingredient Identifier
- 6UXW23996M
- Background
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
- Indication
Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
- Associated Therapies
- -
Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors
- Conditions
- Breast CancerDrug/Agent Toxicity by Tissue/OrganLung CancerLymphomaOvarian CancerUnspecified Adult Solid Tumor, Protocol Specific
- First Posted Date
- 2004-05-24
- Last Posted Date
- 2011-01-10
- Lead Sponsor
- Scripps Health
- Target Recruit Count
- 20
- Registration Number
- NCT00003269
- Locations
- 🇺🇸
Scripps Clinic, La Jolla, California, United States
Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic Lymphoma
- Conditions
- LeukemiaLymphomaMyelodysplastic Syndromes
- First Posted Date
- 2004-05-24
- Last Posted Date
- 2010-02-24
- Lead Sponsor
- Virginia Commonwealth University
- Target Recruit Count
- 19
- Registration Number
- NCT00003187
- Locations
- 🇺🇸
University of South Carolina School of Medicine, Columbia, South Carolina, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States
Combination Chemotherapy and Interferon Alfa With or Without Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloma
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- First Posted Date
- 2004-05-21
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- Medical Research Council
- Target Recruit Count
- 750
- Registration Number
- NCT00002599
- Locations
- 🇬🇧
Leeds Teaching Hospital Trust, Leeds, England, United Kingdom
Combination Chemotherapy Following GM-CSF in Treating Patients With Multiple Myeloma
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- First Posted Date
- 2004-05-21
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 30
- Registration Number
- NCT00003490
- Locations
- 🇺🇸
Cleveland Clinic Cancer Center, Cleveland, Ohio, United States
Combination Chemotherapy in Treating Patients With Extensive Stage Small Cell Lung Cancer
- Conditions
- Lung Cancer
- First Posted Date
- 2004-05-21
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 216
- Registration Number
- NCT00003606
- Locations
- 🇫🇷
Hopital Arnaud de Villeneuve, Montpellier, France
Chemotherapy in Treating Women With Breast Cancer That Can Be Surgically Removed
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2004-05-21
- Last Posted Date
- 2010-02-03
- Lead Sponsor
- NSABP Foundation Inc
- Target Recruit Count
- 2411
- Registration Number
- NCT00002707
- Locations
- 🇺🇸
Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸CCOP - Atlanta Regional, Atlanta, Georgia, United States
🇺🇸Franklin Square Hospital Center, Baltimore, Maryland, United States
Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma
- Conditions
- Lymphoma
- First Posted Date
- 2004-05-20
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- United Kingdom Children's Cancer Study Group
- Target Recruit Count
- 100
- Registration Number
- NCT00003423
- Locations
- 🇬🇧
Hospital for Sick Children NHS Trust, London, England, United Kingdom
Combination Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2004-05-20
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
- Target Recruit Count
- 1000
- Registration Number
- NCT00005581
- Locations
- 🇮🇹
Ospedale S. Paolo, Savona, Italy
🇮🇹Ospedale Oncologico A. Businco, Cagliari, Italy
🇮🇹I.R.C.C.S. Policlinico San Matteo, Pavia, Italy
Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer
- Conditions
- Drug/Agent Toxicity by Tissue/OrganLeukemiaLymphomaMultiple Myeloma and Plasma Cell NeoplasmOral ComplicationsRadiation Toxicity
- First Posted Date
- 2004-05-20
- Last Posted Date
- 2013-06-26
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Registration Number
- NCT00004132
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia
- Conditions
- Leukemia
- Interventions
- First Posted Date
- 2004-05-20
- Last Posted Date
- 2016-07-06
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 163
- Registration Number
- NCT00003700
- Locations
- 🇺🇸
University of Illinois at Chicago Health Sciences Center, Chicago, Illinois, United States
🇺🇸University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸Veterans Affairs Medical Center - Chicago (Westside Hospital), Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.